Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review
Antibiotics · 07.06.2026 · 15 (6) · 581
DOI: 10.3390/antibiotics15060581 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 07.06.2026. Verfasst von Lyudmila Boyanova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
It is crucial to consider newer antibiotics with activity against anaerobes and Helicobacter pylori, given their healthcare importance, and the constantly growing antibiotic resistance/multidrug resistance, which complicates the therapy. The aim of this review was to emphasize certain recently approved or still-under-investigation antibiotics with potential benefits for treating Clostridioides difficile infections (CDIs), other anaerobic infections, and those caused by H. pylori, covering recent data from articles published primarily in 2020–2026. Given the limited number of antibiotics for treating CDI and fidaxomicin nonavailability in many countries, it is necessary to conduct more extensive laboratory and clinical studies of promising antibiotics such as ibezapolstat, delafloxacin, lascufloxacin, omadacycline, eravacycline, ridinilazole, and CRS3123. Against Bacteroides fragilis group species, delafloxacin and eravacycline showed good activity. Research on rifasutenizol for bacterial vaginosis, sarecycline and nadifloxacin for acne vulgaris and amixicile for periodontal diseases needs to be expanded. For H. pylori infection, delafloxacin, sitafloxacin, nemonoxacin, zoliflodacin, and rifasutenizol may improve the suboptimal success of most eradication regimens. However, more efforts, in coordination between medical, scientific, manufacturing, and government representatives, should ensure wider access to and research on the newer antibacterials. Establishing more research groups, careful examination of market issues, and additional approaches, such as nanomaterials, efflux pump inhibitors, phage therapy, and CRISPR-Cas systems, should be beneficial. Notwithstanding the difficulties, there are many opportunities to promote research on and potential use of newer antibiotics which show advantages over the older antibacterials, and to make them available to numerous countries and patients worldwide.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria.
- Faculty of Medicine, University of Coimbra, 3000 Coimbra, Portugal.
- Children's Gastroenterology Clinic, Specialized Hospital for Active Pediatric Treatment "Prof. Dr. Ivan Mitev", Medical University-Sofia, 1431 Sofia, Bulgaria.
ORCID-Profile: Lyudmila Boyanova, Liliya Yordanova Boyanova, José Medeiros, Georgi Dimitrov, Petyo Hadzhiyski, Raina Gergova, Rumyana Markovska
Zitieren
APA
Boyanova, L., Boyanova, L. Y., Medeiros, J., Dimitrov, G., Hadzhiyski, P., Gergova, R., & Markovska, R. (2026). Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review. Antibiotics, 15(6), 581. https://doi.org/10.3390/antibiotics15060581
Vancouver
Boyanova L, Boyanova LY, Medeiros J, Dimitrov G, Hadzhiyski P, Gergova R, et al. Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review. Antibiotics. 2026;15(6):581. doi:10.3390/antibiotics15060581
BibTeX
@article{Boyanova2026,
author = {Boyanova, Lyudmila and Boyanova, Liliya Yordanova and Medeiros, José and Dimitrov, Georgi and Hadzhiyski, Petyo and Gergova, Raina and Markovska, Rumyana},
title = {Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {6},
pages = {581},
doi = {10.3390/antibiotics15060581}
}
EUVIMED